{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Castrate-resistant+Prostate+Cancer+%28CRPC%29&page=7",
    "query": {
      "condition": "Castrate-resistant Prostate Cancer (CRPC)",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 147,
    "total_pages": 15,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Castrate-resistant+Prostate+Cancer+%28CRPC%29&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Castrate-resistant+Prostate+Cancer+%28CRPC%29&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T12:28:56.096Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03569280",
      "title": "Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Castration-Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide or Abiraterone or Apalutamid",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Kangpu Biopharmaceuticals, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 16,
      "start_date": "2019-11-26",
      "completion_date": "2023-06-15",
      "has_results": false,
      "last_update_posted_date": "2023-07-18",
      "last_synced_at": "2026-10-11T12:28:56.096Z",
      "location_count": 3,
      "location_summary": "Las Vegas, Nevada • Port Jefferson Station, New York • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Port Jefferson Station",
          "state": "New York"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03569280"
    },
    {
      "nct_id": "NCT06549465",
      "title": "Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PSMA PET-Positive Castration-Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "In-111 rosopatamab tetraxetan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "45 kBq/kg Ac-225 rosopatamab tetraxetan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "60 kBq/kg Ac-225 rosopatamab tetraxetan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Single dose 22 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Single dose 34 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Single dose 45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "55 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "60 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Convergent Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 93,
      "start_date": "2024-08-06",
      "completion_date": "2031-10",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-11T12:28:56.096Z",
      "location_count": 9,
      "location_summary": "San Diego, California • Boston, Massachusetts • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06549465"
    },
    {
      "nct_id": "NCT02793765",
      "title": "Docetaxel Followed by Provenge in Metastatic Prostate Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Sipuleucel-T",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2016-12",
      "completion_date": "2021-07",
      "has_results": false,
      "last_update_posted_date": "2017-10-30",
      "last_synced_at": "2026-10-11T12:28:56.096Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02793765"
    },
    {
      "nct_id": "NCT01942837",
      "title": "Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 67,
      "start_date": "2013-09-13",
      "completion_date": "2022-09-30",
      "has_results": true,
      "last_update_posted_date": "2022-10-24",
      "last_synced_at": "2026-10-11T12:28:56.096Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Weymouth, Massachusetts • Seattle, Washington",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Weymouth",
          "state": "Massachusetts"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01942837"
    },
    {
      "nct_id": "NCT02135484",
      "title": "Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Alpharadin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2014-09-19",
      "completion_date": "2020-11-11",
      "has_results": true,
      "last_update_posted_date": "2022-02-17",
      "last_synced_at": "2026-10-11T12:28:56.096Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02135484"
    },
    {
      "nct_id": "NCT03690141",
      "title": "An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castrate-resistant Prostate Cancer (CRPC)"
      ],
      "interventions": [
        {
          "name": "eFT508",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Effector Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 16,
      "start_date": "2018-11-27",
      "completion_date": "2020-04-27",
      "has_results": true,
      "last_update_posted_date": "2024-06-21",
      "last_synced_at": "2026-10-11T12:28:56.096Z",
      "location_count": 10,
      "location_summary": "New Haven, Connecticut • Chicago, Illinois • Baltimore, Maryland + 7 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03690141"
    },
    {
      "nct_id": "NCT06705686",
      "title": "Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer (CRPC)",
        "Metastatic Castration-resistant Prostate Carcinoma"
      ],
      "interventions": [
        {
          "name": "(R)-9bMS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TechnoGenesys, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2026-03-13",
      "completion_date": "2028-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-10-11T12:28:56.096Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06705686"
    },
    {
      "nct_id": "NCT01199146",
      "title": "Abiraterone Post Ketoconazole for Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Abiraterone acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 42,
      "start_date": "2010-09-10",
      "completion_date": "2016-03-14",
      "has_results": true,
      "last_update_posted_date": "2018-01-08",
      "last_synced_at": "2026-10-11T12:28:56.096Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Chicago, Illinois",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01199146"
    },
    {
      "nct_id": "NCT02065323",
      "title": "A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Standard ADT",
          "type": "DRUG"
        },
        {
          "name": "Dovitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oscar Goodman, Jr.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-01-19",
      "last_synced_at": "2026-10-11T12:28:56.096Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02065323"
    },
    {
      "nct_id": "NCT02361086",
      "title": "A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Castration-resistant Prostate Cancer",
        "CRPC"
      ],
      "interventions": [
        {
          "name": "VT-464: given orally once daily in 28 day cycles",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Innocrin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 21,
      "start_date": "2014-06",
      "completion_date": "2018-06",
      "has_results": false,
      "last_update_posted_date": "2019-02-01",
      "last_synced_at": "2026-10-11T12:28:56.096Z",
      "location_count": 5,
      "location_summary": "Tampa, Florida • Omaha, Nebraska • Durham, North Carolina + 2 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Myrtle Beach",
          "state": "South Carolina"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02361086"
    }
  ]
}